...cGMP levels and patients exhibited no adverse events.Intra-Cellular Therapies Inc....
...where the MOA involves preventing breakdown of cGMP. Intra-Cellular...
...—the company’s primary focus.  In June, Intra-Cellular...

...and Amgen both said COVID-19 had affected new patient starts.Similarly, 2Q sales of Caplyta lumateperone from Intra-Cellular Therapies Inc....

...board of PureTech Health plc (LSE:PRTC). Mazumdar-Shaw is the co-founder and executive chairperson of Biocon Ltd. (NSE:BIOCON; BSE:532523).Intra-Cellular...

...By Lauren Martz, Senior Editor Intra-Cellular added $903.9...
...submission planned for late 2020 or early 2021.Intra-Cellular Therapies Inc....
...III monotherapy trials that read out last year (see “Intra-Cellular...

...CSO by Kimberly Vanover, who was SVP, early stage clinical development and translational medicine at Intra-Cellular Therapies Inc....
...hired Eve Taylor as VP, clinical development. She was senior director of clinical development at Intra-Cellular...

...Investors view FDA’s willingness to consider aducanumab and its recent approval of Caplyta lumateperone from Intra-Cellular Therapies Inc....
...to treat schizophrenia based on a combination of late-stage hits and misses. The approval sent Intra-Cellular’s...

...Intra-Cellular raises $295M In an offering priced late Tuesday, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) raised $295 million through the...
...Intra-Cellular’s close at $30.62 on Monday, when the company proposed the offering after market hours. Intra-Cellular...
...Morgan, SVB Leerink, Evercore, Cantor Fizgerald, Canaccord Genuity and JMP Securities (see “Unanticipated Approval Lifts Intra-Cellular...

...Emerging from a cloud of regulatory questions and mixed clinical results, Intra-Cellular has received FDA approval...
...a Phase III miss left investors unsure about the drug’s odds of approval. In August, Intra-Cellular Therapies Inc....
...readout (see “Intra-Cellular Optimistic on Lumateperone’s Future in Bipolar Despite Mixed Phase III Results” ). Intra-Cellular...

...patients with advanced solid tumors, excluding brain cancers. Intra-Cellular issues FDA update on lumateperone NDA Intra-Cellular Therapies Inc....
...FDA's request for additional toxicology information on the product. The PDUFA date is Dec. 27. BC Staff Intra-Cellular Therapies Inc. Lexicon...

...candidate is a designed ankyrin repeat protein that antagonizes VEGF-A. Delay for Intra-Cellular's schizophrenia NDA Intra-Cellular Therapies Inc....
...patisiran (ALN-TTR02, GENZ438027, GZ438027, SAR438027) sintilimab (IBI308) tafasitamab (MOR00208, MOR208, xmab5574) Allergan plc Alnylam Pharmaceuticals Inc. GW Pharmaceuticals plc Innovent Biologics Inc. Intra-Cellular Therapies Inc. Molecular...